These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31864730)

  • 1. Titration of Igs contained in an intravenous IgM-enriched preparation against selected pathogens involved in sepsis.
    Stracquadanio S; Lo Verde F; Cialfi A; Zega A; Stefani S; Cafiso V
    Immunobiology; 2020 Mar; 225(2):151897. PubMed ID: 31864730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and potential clinical applications of Pentaglobin, an IgM-enriched immunoglobulin concentrate suitable for intravenous infusion.
    Lissner R; Struff WG; Autenrieth IB; Woodcock BG; Karch H
    Eur J Surg Suppl; 1999; (584):17-25. PubMed ID: 10890227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentaglobin (immunoglobulin M-enriched immunoglobulin) as adjuvant therapy for premature and very low-birth-weight neonates with sepsis.
    Nassir KF; Al-Saddi YI; Abbas HM; Al Khames Aga QA; Al Khames Aga LA; Oudah AA
    Indian J Pharmacol; 2021; 53(5):364-370. PubMed ID: 34854404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens.
    Rossmann FS; Kropec A; Laverde D; Saaverda FR; Wobser D; Huebner J
    Infection; 2015 Apr; 43(2):169-75. PubMed ID: 25428225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyvalent immunoglobulin significantly attenuated the formation of IL-1β in Escherichia coli-induced sepsis in pigs.
    Barratt-Due A; Sokolov A; Gustavsen A; Hellerud BC; Egge K; Pischke SE; Lindstad JK; Pharo A; Castellheim A; Thorgersen EB; Mollnes TE
    Immunobiology; 2013 May; 218(5):683-9. PubMed ID: 22947599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization of disease associated autoantibodies by an immunoglobulin M- and immunoglobulin A-enriched human intravenous immunoglobulin preparation.
    Bar-Dayan Y; Bonnin E; Bloch M; Schweitzer R; Ravid M; Kazatchkine MD; Kaveri SV
    Scand J Immunol; 2000 Apr; 51(4):408-14. PubMed ID: 10736114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis.
    Norrby-Teglund A; Haque KN; Hammarström L
    J Intern Med; 2006 Dec; 260(6):509-16. PubMed ID: 17116001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to Gram-positive and Gram-negative bacteria and their cell wall components.
    Dziarski R; Wang Q; Miyake K; Kirschning CJ; Gupta D
    J Immunol; 2001 Feb; 166(3):1938-44. PubMed ID: 11160242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins.
    Behre G; Schedel I; Nentwig B; Wörmann B; Essink M; Hiddemann W
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2139-46. PubMed ID: 1444293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin.
    Garbett ND; Munro CS; Cole PJ
    Clin Exp Immunol; 1989 Apr; 76(1):8-12. PubMed ID: 2500275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Properties and efficacy of a human immunoglobulin M preparation for intravenous administration].
    Stephan W; Dichtelmüller H; Schedel I
    Arzneimittelforschung; 1985; 35(6):933-6. PubMed ID: 4026919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism.
    Wang JE; Dahle MK; McDonald M; Foster SJ; Aasen AO; Thiemermann C
    Shock; 2003 Nov; 20(5):402-14. PubMed ID: 14560103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response of non-pathogenic gram(+) and gram(-) bacteria in inductive sites of the intestinal mucosa study of the pathway of signaling involved.
    Dogi CA; Weill F; Perdigón G
    Immunobiology; 2010; 215(1):60-9. PubMed ID: 19250703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The therapy of gram-negative septicotoxic diseases with pentaglobin, an immunoglobulin with an elevated IgM content (a prospective, randomized clinical study)].
    Schedel I; Dreichhausen U
    Anesteziol Reanimatol; 1996; (3):4-9. PubMed ID: 8967617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of immunoglobulin M-enriched intravenous immunoglobulins against bacterial infections and on the neutralization of bacterial toxins].
    Dichtelmüller H; Stephan W
    Arzneimittelforschung; 1987 Nov; 37(11):1273-6. PubMed ID: 3440036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components.
    Takeuchi O; Hoshino K; Kawai T; Sanjo H; Takada H; Ogawa T; Takeda K; Akira S
    Immunity; 1999 Oct; 11(4):443-51. PubMed ID: 10549626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia.
    Hoffman JN; Fertmann JM; Vollmar B; Laschke MW; Jauch KW; Menger MD
    Shock; 2008 Jan; 29(1):133-9. PubMed ID: 18246604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin).
    Nachbaur D; Herold M; Gächter A; Niederwieser D
    Immunology; 1998 Jun; 94(2):279-83. PubMed ID: 9741353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opsonic activity assessment of human intravenous immunoglobulin preparations against drug-resistant bacteria.
    Ono Y; Ito T; Watanabe T; Koshio O; Tansho S; Ikeda T; Kawakami S; Miyazawa Y
    J Infect Chemother; 2004 Aug; 10(4):234-8. PubMed ID: 15365865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis.
    Nau R; Eiffert H
    Clin Microbiol Rev; 2002 Jan; 15(1):95-110. PubMed ID: 11781269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.